These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20574648)

  • 41. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E; Kageyama Y; Takahashi M; Nagano A
    Mod Rheumatol; 2006; 16(6):350-4. PubMed ID: 17164995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serological identification of fast progressors of structural damage with rheumatoid arthritis.
    Siebuhr AS; Bay-Jensen AC; Leeming DJ; Plat A; Byrjalsen I; Christiansen C; van de Heijde D; Karsdal MA
    Arthritis Res Ther; 2013 Aug; 15(4):R86. PubMed ID: 23945134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab.
    Hirao M; Hashimoto J; Tsuboi H; Nampei A; Nakahara H; Yoshio N; Mima T; Yoshikawa H; Nishimoto N
    Ann Rheum Dis; 2009 May; 68(5):654-7. PubMed ID: 18519424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
    Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tocilizumab for rheumatoid arthritis.
    Singh JA; Beg S; Lopez-Olivo MA
    Cochrane Database Syst Rev; 2010 Jul; (7):CD008331. PubMed ID: 20614469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
    Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S
    Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
    Buckley F; Finckh A; Huizinga TW; Dejonckheere F; Jansen JP
    J Manag Care Spec Pharm; 2015 May; 21(5):409-23. PubMed ID: 25943002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.
    Finckh A; Simard JF; Duryea J; Liang MH; Huang J; Daneel S; Forster A; Gabay C; Guerne PA
    Arthritis Rheum; 2006 Jan; 54(1):54-9. PubMed ID: 16385495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.
    Jansen JP; Vieira MC; Bradley JD; Cappelleri JC; Zwillich SH; Wallenstein GV
    BMC Musculoskelet Disord; 2016 Aug; 17(1):348. PubMed ID: 27538585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New biologics for rheumatoid arthritis.
    Choy E
    J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts.
    Carpenter L; Norton S; Nikiphorou E; Jayakumar K; McWilliams DF; Rennie KL; Dixey J; Kiely P; Walsh DA; Young A;
    Arthritis Care Res (Hoboken); 2017 Dec; 69(12):1809-1817. PubMed ID: 28217885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger.
    Kamishima T; Tanimura K; Shimizu M; Matsuhashi M; Fukae J; Kon Y; Hagiwara H; Narita A; Aoki Y; Kosaka N; Atsumi T; Shirato H; Terae S
    Skeletal Radiol; 2011 Jun; 40(6):745-55. PubMed ID: 21076827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
    Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.
    Landewé R; Smolen JS; Florentinus S; Chen S; Guérette B; van der Heijde D
    Arthritis Res Ther; 2015 May; 17(1):133. PubMed ID: 25994819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.